| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c501c9e2c4a7c0209942985018c9222f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9cb51d662b3a8a8dba496f865f5f9f67
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2caffa7616acda9cfa376da3444af03e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e5c62b2bebb10ca49b2adca81c2a21f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f6ceb03535d5ed67a165da49e725357a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4738
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2002-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c776fef9c60dd41f88d11e79d83eaa19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3ff6e026e9f98d348ea2c30213e5c93
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc3927fd9b3ecaeecce01e6c205061ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65aa91209e7c3b1608cb6f5f8785b901 |
| publicationDate |
2003-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-03033520-A2 |
| titleOfInvention |
Anticancer vaccine and diganostic methods and reagents |
| abstract |
The invention provides a method of priming T cells against tumor antigens comprising by obtaining naïve CD4?+ or DC8+¿ T cells from at least one healthy individual, obtaining at least one protein or peptide from at least one cancerous cell; obtaining antigen presenting cells (APCs), culturing the APCs with the at least one protein or peptide, and adding the T cells to the culture of the APCs. The primed T cells can then be employed to identify the antigens or therapeutically as prophylaxis or treatment for cancers. The invention also provides cyclin molecules, and fragments derived from cyclin molecules, as tumor antigens. The invention provides a method for diagnosing a malignant or pre-malignant condition within a patient. The invention also provides a method for vaccinating a patient against malignancies comprising introducing a protein or peptide consisting essentially of all or an immunogenic fragment of a cyclin protein into the patient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007140953-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-3008099-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11325962-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-3090319-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10550166-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020127996-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9469684-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015001526-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1864996-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8211436-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8956612-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8748170-B2 |
| priorityDate |
2001-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |